PTC Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . PTC Therapeutics
PTCT Stock  USD 43.84  0.76  1.76%   
PTC Therapeutics financial statements provide useful quarterly and yearly information to potential PTC Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on PTC Therapeutics financial statements helps investors assess PTC Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting PTC Therapeutics' valuation are summarized below:
Gross Profit
299.4 M
Profit Margin
(0.50)
Market Capitalization
3.3 B
Enterprise Value Revenue
2.9389
Revenue
900.7 M
There are currently one hundred twenty fundamental measures for PTC Therapeutics that can be evaluated and compared over time across peers in the sector. All traders should check out PTC Therapeutics' latest fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Enterprise Value is likely to gain to about 3.5 B in 2025, whereas Market Cap is likely to drop slightly above 1.3 B in 2025.

PTC Therapeutics Total Revenue

1.13 Billion

Check PTC Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among PTC Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 156 M, Total Revenue of 1.1 B or Research Development of 804.9 M, as well as many indicators such as Price To Sales Ratio of 2.4, Dividend Yield of 0.0 or Days Sales Outstanding of 51.74. PTC financial statements analysis is a perfect complement when working with PTC Therapeutics Valuation or Volatility modules.
  
Check out the analysis of PTC Therapeutics Correlation against competitors.
For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide.

PTC Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets2.3 B2.2 B1 B
Slightly volatile
Other Current Liabilities466 M443.8 M148.2 M
Slightly volatile
Total Current Liabilities728.2 M693.6 M244.9 M
Slightly volatile
Other Liabilities263.2 M309.9 M262 M
Slightly volatile
Accounts Payable9.9 M7 M9.4 M
Slightly volatile
Cash717.3 M683.1 M339.5 M
Slightly volatile
Other Assets40.3 M38.4 M17.2 M
Slightly volatile
Short Term Investments281.6 M325.1 M260.1 M
Slightly volatile
Total Liabilities3.3 B3.1 B1.1 B
Slightly volatile
Property Plant Equipment87.7 M83.5 M36.2 M
Slightly volatile
Short and Long Term Debt Total2.7 B2.6 B641.5 M
Slightly volatile
Property Plant And Equipment Net216.1 M205.8 M70.6 M
Slightly volatile
Current Deferred Revenue875.1 K921.1 K22.4 M
Pretty Stable
Non Current Assets Total479.9 M778.6 M433.8 M
Slightly volatile
Non Currrent Assets Other34.8 M41.7 M30.5 M
Slightly volatile
Cash And Short Term Investments1.1 B1 B464 M
Slightly volatile
Net Receivables194.4 M185.2 M67.8 M
Slightly volatile
Common Stock Total Equity45.3 K82.8 K43.4 K
Slightly volatile
Common Stock Shares Outstanding49.7 M86.1 M46.7 M
Slightly volatile
Liabilities And Stockholders Equity2.3 B2.2 B1 B
Slightly volatile
Non Current Liabilities Total2.5 B2.4 B848.9 M
Slightly volatile
Property Plant And Equipment Gross278 M264.8 M85.4 M
Slightly volatile
Total Current Assets1.5 B1.4 B581 M
Slightly volatile
Short Term Debt254 M241.9 M77.8 M
Slightly volatile
Common Stock48.1 K86.2 K44 K
Slightly volatile
Capital Surpluse1.6 B2.7 B1.3 B
Slightly volatile
Non Current Liabilities Other154 K162.2 K231.5 M
Slightly volatile
Long Term Debt Total690.4 M657.5 M270.5 M
Slightly volatile
Short and Long Term Debt234.6 M223.5 M115.6 M
Slightly volatile
Net Invested Capital1.5 B1.5 B598 M
Slightly volatile
Net Working Capital497.7 M707.9 M346.4 M
Slightly volatile
Capital Stock73.5 K86.2 K60.5 K
Slightly volatile
Capital Lease Obligations131.4 M150.4 M117 M
Slightly volatile

PTC Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Revenue1.1 B1.1 B364.8 M
Slightly volatile
Research Development804.9 M766.5 M309.6 M
Slightly volatile
Depreciation And Amortization285.7 M272.1 M73.6 M
Slightly volatile
Selling General Administrative421.4 M401.3 M173.5 M
Slightly volatile
Other Operating Expenses1.6 B1.5 B567.7 M
Slightly volatile
Total Operating Expenses1.6 B1.5 B565 M
Slightly volatile
Interest Income10.5 M14.4 M8.4 M
Slightly volatile
Reconciled Depreciation235.2 M224 M68.1 M
Slightly volatile
Non Recurring26.7 M30 M32.8 M
Slightly volatile

PTC Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capital Expenditures145.6 M138.7 M48.4 M
Slightly volatile
End Period Cash Flow736.9 M701.8 M223.5 M
Slightly volatile
Stock Based Compensation158.4 M150.9 M58.5 M
Slightly volatile
Begin Period Cash Flow357.3 M340.3 M140.9 M
Slightly volatile
Depreciation285.7 M272.1 M73 M
Slightly volatile
Other Non Cash Items182.7 M174 M55.6 M
Slightly volatile
Sale Purchase Of Stock89.2 M64 M119.8 M
Slightly volatile
Change To Netincome79 M130.8 M67.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.42.5310.6582
Pretty Stable
Days Sales Outstanding51.7456.459.5933
Slightly volatile
Average Payables2.1 M2.4 M2.6 M
Slightly volatile
Stock Based Compensation To Revenue0.310.160.2599
Very volatile
Capex To Depreciation0.610.460.6904
Pretty Stable
EV To Sales4.314.539.5032
Pretty Stable
Inventory Turnover1.041.930.9395
Slightly volatile
Days Of Inventory On Hand186196573
Slightly volatile
Sales General And Administrative To Revenue0.80.520.7764
Very volatile
Research And Ddevelopement To Revenue1.540.821.3192
Pretty Stable
Capex To Revenue0.07440.120.0878
Slightly volatile
Cash Per Share9.1510.5410.6536
Slightly volatile
Intangibles To Total Assets0.470.280.3836
Pretty Stable
Current Ratio4.492.323.7857
Pretty Stable
Receivables Turnover6.366.717.4939
Slightly volatile
Graham Number42.940.8526.9028
Slightly volatile
Capex Per Share1.521.450.6459
Slightly volatile
Average Receivables1.2 M1.1 M1 M
Very volatile
Revenue Per Share11.8411.286.084
Slightly volatile
Interest Debt Per Share29.7828.368.5499
Slightly volatile
Debt To Assets1.111.060.4159
Slightly volatile
Operating Cycle223210254
Slightly volatile
Ebt Per Ebit0.951.791.1929
Slightly volatile
Quick Ratio4.442.273.7474
Pretty Stable
Net Income Per E B T1.111.041.0119
Very volatile
Cash Ratio1.081.132.3447
Pretty Stable
Days Of Inventory Outstanding186196573
Slightly volatile
Days Of Sales Outstanding51.7456.459.5933
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.01.591.2435
Slightly volatile
Fixed Asset Turnover6.774.728.1622
Very volatile
Debt Ratio1.111.060.4159
Slightly volatile
Price Sales Ratio2.42.5310.6582
Pretty Stable
Asset Turnover0.630.570.6777
Slightly volatile

PTC Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.3 B1.9 B1.5 B
Slightly volatile
Enterprise Value3.5 B3.3 B1.8 B
Slightly volatile

PTC Fundamental Market Drivers

Forward Price Earnings16.5017
Cash And Short Term Investments876.7 M

PTC Upcoming Events

20th of February 2024
Upcoming Quarterly Report
View
25th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About PTC Therapeutics Financial Statements

PTC Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although PTC Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in PTC Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on PTC Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue921.1 K875.1 K
Total Revenue1.1 B1.1 B
Cost Of Revenue58.9 M36.5 M
Stock Based Compensation To Revenue 0.16  0.31 
Sales General And Administrative To Revenue 0.52  0.80 
Research And Ddevelopement To Revenue 0.82  1.54 
Capex To Revenue 0.12  0.07 
Revenue Per Share 11.28  11.84 
Ebit Per Revenue(0.34)(0.35)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for PTC Stock Analysis

When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY